4 Institute of Pathology and Comprehensive Cancer Center EMN, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany Objectives CD19-targeting chimeric ...

NKTR-255 with CD19 chimeric antigen receptor T-cell therapy improved 6-month complete response rates in relapsed/refractory large B-cell lymphoma. The combination of NKTR-255 with CD19-directed ...

Anti-CD19 chimeric antigen receptor (CD19-CAR)-engineered T cells are approved therapeutics for malignancies. The impact of the hinge domain (HD) and the transmembrane domain (TMD) between the ...

Here, we review the ongoing developments with CAR T cells in the field of autoimmune disorders. We will cover first clinical results of applying anti-CD19 and anti-B cell maturation antigen CAR T ...

which directs them to CD19 antigens on B-cell cancers. In the absence of the antibody, the CAR-T cells are dormant. The first readout from an ongoing phase 1 study reveals that, out of nine ...

Yescarta – a CD19-directed genetically modified autologous T-cell immunotherapy investigated in the ZUMA-1 trial – is the first chimeric antigen receptor (CAR) T-cell therapy recommended for ...

A previous study 3 used commercially aggregated electronic health record data and diagnosis codes to identify systemic autoimmune rheumatic diseases and lymphoma treated with CD19-targeted CAR T-cell ...

Catalent global cell therapy and plasmid DNA vice-president Delara ... GLPG5101 is an anti-cluster of differentiation 19 (CD19)/4-1BB CAR-T candidates, designed to be administered in a single ...

CHICAGO--(BUSINESS WIRE)--VectorBuilder's partner, Ucello, announced that its CD19-targeting umbilical cord blood-derived allogeneic CAR-T cell therapy ... does not require plasmid DNA as critical ...